{
  "chapter": "Neurology-Parkinsonism And Parkinson S Disease",
  "questions": [
    {
      "q_no": 1,
      "question": "A 62-year-old man presents to the medicine clinic with complaints of postural instability, frequent falls, and urinary incontinence over the past year. His family reports that he has also been experiencing difficulty with coordination and has developed a noticeable tremor. Neurological examination reveals bradykinesia, rigidity, and dysarthria. An MRI of the brain is performed and the image is shown below. What MRI finding is likely to be seen in this patient?",
      "options": {
        "A": "Iron deposition in the brain’s striatum",
        "B": "Hot cross bun sign in the pons",
        "C": "Hummingbird sign",
        "D": "Red nucleus degeneration"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Hot cross bun sign in the pons Explanation: Based on the clinical manifestation, the most probable diagnosis is Multiple-system atrophy- cerebellum (MSA-c). The \"hot cross bun sign\" is an MRI",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Neurology-Parkinsonism_And_Parkinson_S_Disease_Q1_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 2,
      "question": "Which of the following is NOT a characteristic common to both tauopathies and synucleinopathies? α -synuclein protein",
      "options": {
        "A": "Neurodegeneration caused by protein aggregation",
        "B": "Spread of aggregates through cell-to-cell transmission",
        "C": "Predominant involvement of",
        "D": "Pathological findings include neuronal inclusions and glial inclusions"
      },
      "correct_answer": "C",
      "explanation": "α -synuclein protein Correct Answer: C) Predominant involvement of α -synuclein protein Explanation: Tauopathies are caused by tau protein aggregation, not α -synuclein, so this is specific only to synucleinopathies. Tauopathies Synucleinopathies Neurodegenerative diseases are caused by tau protein aggregation. This leads to neurodegeneration, affecting cognition and motor function. Tau aggregates spread through cell-to-cell transmission, advancing disease progression. Common Tauopathies: Alzheimer’s Disease (AD) Pick’s Disease (PiD) Progressive Supranuclear Palsy (PSP) Corticobasal Degeneration (CBD): Chronic Traumatic Encephalopathy (CTE) Pathological Classification: Tauopathies are categorised by tau isoforms: 3R, 4R, and 3R/4R. Neurodegenerative diseases marked by α -synuclein protein aggregation. α -Syn aggregates cause neurodegeneration, spreading through the brain and contributing to disease progression. Common Synucleinopathies: Parkinson’s Disease (PD) Dementia with Lewy Bodies (DLB) Multiple System Atrophy (MSA) Neuropathological Findings: Neuronal inclusions, astrocytic pathology, and glial inclusions in the affected areas. Tau and α -syn protein aggregation leads to neurotoxicity, resulting in: Synaptic dysfunction Neuronal loss Behavioural abnormalities Neurodegeneration caused by protein aggregation (Option A) : Both tauopathies and synucleinopathies involve neurodegeneration due to protein aggregation (tau in tauopathies, α -synuclein in synucleinopathies). Spread of aggregates through cell-to-cell transmission (Option B) : Tau and α -syn aggregates spread via cell-to-cell transmission, contributing to disease progression in both conditions. Pathological findings include neuronal inclusions and glial inclusions (Option D) : Both tauopathies and synucleinopathies show similar neuropathological features, including neuronal and glial inclusions. Reference: pmc.ncbi.nlm.nih.gov/articles/PMC7529725/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 3,
      "question": "A 70-year-old man with advanced Parkinson's disease is considered for deep brain stimulation (DBS) after experiencing significant motor fluctuations and dyskinesias despite optimal medication therapy. Which of the following brain structures is most commonly targeted in DBS to improve tremor, bradykinesia, and rigidity?",
      "options": {
        "A": "Ventral Intermediate Nucleus of the Thalamus",
        "B": "Subthalamic Nucleus (STN)",
        "C": "Globus Pallidus Internus (GPi)",
        "D": "Caudate Nucleus"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Subthalamic Nucleus (STN) Explanation: STN stimulation has been shown to improve tremor, bradykinesia, and rigidity in patients with Parkinson's disease. C(DBS) in Parkinson's Disease: Mechanism of Action: Electrical Impulses : DBS delivers electrical impulses to specific brain regions, modulating abnormal neural circuits involved in motor control. Neuronal Firing : It is believed that DBS increases the firing rate of neurons in stimulated areas, improving motor function, although the precise mechanisms are not fully understood. Targeted Brain Structures: Subthalamic Nucleus (STN) : Improves tremor, bradykinesia, and rigidity. Globus Pallidus Internus (GPi) : Reduces dyskinesias and enhances overall motor function. Ventral Intermediate Nucleus of the Thalamus : Primarily used for tremor reduction. Indications: Patient Profile : Indicated for patients with advanced Parkinson's disease experiencing significant motor fluctuations or dyskinesias despite optimal medical therapy. Quality of Life : Can significantly enhance the quality of life by improving motor control and reducing medication side effects. Risks and Side Effects: Common Risks : Mild gait or speech disturbances Mood changes (depression, affective lability) Cognitive issues (difficulty concentrating, confusion) Seizures Headaches Outcome : Despite potential risks, many patients experience substantial improvements in symptoms and overall functioning. Ventral Intermediate Nucleus of the Thalamus (Option A) : Primarily used for tremor reduction, not specifically for improving bradykinesia and rigidity. This option is incorrect for the indicated symptoms. Globus Pallidus Internus (GPi) (Option C) : While it reduces dyskinesias and improves motor function, it is not primarily targeted for tremors, bradykinesia, and rigidity. This option is incorrect for this specific case. Caudate Nucleus (Option D) : This structure is not commonly targeted in DBS for Parkinson's disease. This option is incorrect as it does not address the primary goals of DBS therapy in PD. Reference: https://www.ncbi.nlm.nih.gov/books/NBK557847/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 4,
      "question": "A 68-year-old woman with Parkinson's disease has been on levodopa therapy but continues to experience significant \"off\" time, where her symptoms worsen before her next dose. Her neurologist is considering adding a medication to enhance her treatment regimen. Which of the following classes of drugs is most appropriate for reducing \"off\" time in this patient?",
      "options": {
        "A": "Benzodiazepines",
        "B": "Anticholinergic agents",
        "C": "Adenosine A2A receptor antagonists",
        "D": "Dopamine agonists"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Adenosine A2A receptor antagonists Explanation: These antagonists enhance D2 receptor-mediated signalling, improving dopaminergic function and specifically reducing \"off\" time when used as an adjunct therapy to levodopa. Adenosine A2A Receptor Antagonists: Mechanism of Action : Receptor Interaction : A2A receptors interact with dopamine D2 receptors, and their activation inhibits D2 signalling, worsening motor symptoms in PD. Dopamine Signalling : Antagonists block A2A receptors, enhancing D2 receptor-mediated signalling, and improving dopaminergic function and motor control. Clinical Applications : Adjunct Therapy : Used alongside levodopa to reduce \"off\" time (periods of worsening symptoms) without increasing the risk of dyskinesia from higher levodopa doses. MAO-B Inhibitors: Mechanism of Action : Dopamine Breakdown : Block the MAO-B enzyme, which breaks down dopamine, increasing dopamine levels in the brain and enhancing dopaminergic signalling. Clinical Benefits : Symptomatic Relief : Improve motor and non-motor symptoms, reducing \"OFF\" time. Monotherapy and Adjunct Therapy : Effective as monotherapy in early PD or as adjuncts to levodopa in advanced stages. Neuroprotective Effects : Potentially delay alpha-synuclein aggregation, possibly slowing disease progression. Approved MAO-B Inhibitors : Selegiline : An irreversible inhibitor used for many years. Rasagiline : A second-generation irreversible inhibitor, more potent than selegiline. Safinamide : A reversible inhibitor with additional mechanisms, including modulating glutamate release. Benzodiazepines (Option A) : These are used for anxiety or sleep disturbances but have no effect on reducing \"off\" time in Parkinson's disease. Anticholinergic agents (Option B) : These medications are primarily used to manage tremors and do not address \"off\" time. This option is incorrect as they do not effectively target the issue of motor fluctuations. Dopamine agonists (Option D) : Although they can provide some benefit, they are generally less effective than levodopa and do not specifically target the reduction of \"off\" time. This option is incorrect as it may not adequately resolve the patient's symptoms. Reference: Adenosine A2A Receptor Antagonist - https://pmc.ncbi.nlm.nih.gov/articles/PMC2583202/ MAO-B inhibitors - https://pmc.ncbi.nlm.nih.gov/articles/PMC8925102/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 5,
      "question": "A 65-year-old man with Parkinson's disease is currently on levodopa therapy but is experiencing significant motor fluctuations and \"wearing off\" between doses. His neurologist is considering adding a medication to improve his overall motor function. Which of the following is a commonly used dopamine agonist that could be added to his treatment regimen?",
      "options": {
        "A": "Ropinirole",
        "B": "Selegiline",
        "C": "Entacapone",
        "D": "Trihexyphenidyl"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Ropinirole Explanation: Ropinirole is a non-ergot-derived dopamine agonist that can be used to enhance motor function and address \"wearing off\" symptoms in Parkinson's disease patients. Dopamine Agonists in Parkinson's Disease: Dopamine and Parkinson's Disease : Dopamine deficiency : Parkinson's disease (PD) is characterised by the loss of dopamine-producing cells in the substantia nigra. Levodopa as a replacement : Levodopa (LD) is the most effective treatment for PD, serving as a precursor to dopamine and essential for managing symptoms. Dopamine Agonists : Treatment option : Dopamine agonists are included in the management of PD. Examples : Ergot-derived : bromocriptine (used for prolactinoma in pregnant females), lisuride, pergolide, cabergoline Non-ergot-derived : Ropinirole - used for restless leg syndrome Pramipexole- Used orally Rotigotine- Used as a transdermal patch Apomorphine- Used as an S/C injection to rescue from the OFF phase Efficacy : Generally less effective than levodopa in relieving parkinsonism symptoms. Potential side effects : Nausea, vomiting, disorientation, hallucinations, and impulse control disorders. Uncertain role : The precise role of dopamine agonists in PD treatment is unclear, with limited evidence supporting their use as initial monotherapy. Selegiline (Option B) : This is a MAO-B inhibitor that can provide some symptomatic relief but is not classified as a dopamine agonist. This option is incorrect because it does not fit the category of dopamine agonists. Entacapone (Option C) : This is a COMT inhibitor used to prolong the effects of levodopa but is not a dopamine agonist. This option is incorrect as it does not meet the requirement of being a dopamine agonist. Trihexyphenidyl (Option D) : This is an anticholinergic medication primarily used for tremor control but is not a dopamine agonist. This option is incorrect as it does not belong to the category of dopamine agonists. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page: 1112, 1113, 1114. www.ajog.org/article/0002-9378(83)90968-7/abstract www.ncbi.nlm.nih.gov/books/NBK554532/#:~:text=Ropinirol e%20is%20a%20drug%20that,channels%20while%20activating%20potassium%20channels. www.mayoclinic.org/drugs-supplements/pramipexole-oral-route/description/drg-20065603 www.mayoclinic.org/drugs-supplements/rotigotine-transdermal-route/description/drg-20071097 www.sciencedirect. com/topics/neuroscience/apomorphine#:~:text=Apomorphine%20injections%20provide%20quick%20and,and%20s upported%20by%20clinical%20experience.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 6,
      "question": "A 70-year-old man with a diagnosis of Parkinson's disease has been experiencing increased motor fluctuations despite being on a stable dose of levodopa for the past two years. He reports that his symptoms improve shortly after taking his medication but then return before his next dose is due. The physician considers adding a medication to help extend the effect of his current treatment. Which of the following is the most appropriate addition to his regimen?",
      "options": {
        "A": "Dopamine agonist",
        "B": "COMT inhibitor",
        "C": "Anticholinergic agent",
        "D": "Beta blocker"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) COMT inhibitor Explanation: COMT inhibitors, such as entacapone, block the breakdown of levodopa, thereby extending its duration of action and addressing the \"wearing off\" phenomenon. Levodopa and COMT Inhibitors in Parkinson's Treatment Role of Levodopa (LD) : Precursor to dopamine : LD is converted into dopamine in the body. Dopamine deficiency : Parkinson's disease (PD) is characterized by the loss of dopamine-producing cells in the substantia nigra, making dopamine replacement crucial for symptom management. Effectiveness : LD is highly effective in relieving movement-related symptoms of PD, particularly akinesia (difficulty initiating movement) and rigidity. Concept of COMT Inhibition : COMT function : Catechol-O-methyltransferase (COMT) is involved in the peripheral breakdown of levodopa. Prolonging levodopa's effect : COMT inhibitors, such as entacapone and peripheral COMT inhibitors- block the breakdown of LD, thereby extending its duration of action. This helps address the \"wearing off\" phenomenon, where symptoms return before the next dose is due. Tolcapone-peripheral and central COMT inhibitor Dopamine agonist (Option A) : These medications mimic dopamine effects in the brain and can be used in Parkinson's treatment but do not specifically address the issue of \"wearing off\" associated with levodopa therapy. This option is incorrect as it does not directly prolong the effect of levodopa. Anticholinergic agent (Option C) : These medications can help with tremors in early PD but are not effective in managing motor fluctuations or \"wearing off\" associated with levodopa. This option is incorrect as it does not address the patient’s specific issue. Beta-blocker (Option D) : Beta-blockers are used for managing symptoms like tremors or hypertension but do not have an effect on extending levodopa's duration of action or reducing \"wearing off.\" Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page: 1113, 1114. pubmed.ncbi.nlm.nih.g ov/11440283/#:~:text=Entacapone%20is%20a%20selective%20inhibitor,in%20the%20central%20nervous%20syst em. www.tandfonline.com/doi/pdf/10.1080/14737175.2021.1968298",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 7,
      "question": "A 68-year-old woman presents with a 1-year history of progressive difficulty controlling her right arm. She reports that her arm occasionally moves on its own, and she has trouble performing simple tasks like buttoning her shirt. On examination, she has dystonic posturing of the right hand, mild bradykinesia, and intermittent myoclonic jerks. Her cognitive function appears intact except for mild apraxia. What is the most likely diagnosis?",
      "options": {
        "A": "Parkinson's disease",
        "B": "Corticobasal syndrome",
        "C": "Multiple system atrophy",
        "D": "Progressive supranuclear palsy"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Corticobasal syndrome Explanation: A neurodegenerative condition involving parkinsonism, dystonia, myoclonus, and cortical features such as apraxia and the alien limb phenomenon. This option is correct as the patient's symptoms, including dystonia, myoclonus, and alien limb, are classic for corticobasal syndrome. Corticobasal Degeneration/Syndrome (CBD): Less common Parkinsonian syndrome : CBD is less frequent compared to Multiple System Atrophy (MSA) or Progressive Supranuclear Palsy (PSP) Variable clinical features : Parkinsonism : Includes tremor, rigidity, and bradykinesia (slow movements) Dystonia : Involuntary muscle contractions causing abnormal postures or movements Myoclonus : Sudden, brief, involuntary muscle jerks Alien limb phenomenon : A limb acts independently of conscious control Cortical symptoms : Dementia : Cognitive decline in memory, thinking, and reasoning Apraxia : Difficulty performing learned movements despite normal physical ability Prominent cortical symptoms : Dementia and apraxia may be the sole presenting features CBD as a tauopathy : Characterised by the abnormal accumulation of tau protein in the brain Distinguishes CBD from Parkinson's disease and MSA, which involve alpha-synuclein protein Widespread tau deposition : Tau protein builds up throughout the brain Limited treatment options : No cure is available and management focuses on symptom relief Similar survival rates : Life expectancy in CBD is comparable to MSA and PSP Parkinson's disease (Option A) : A neurodegenerative disorder primarily characterised by tremor, bradykinesia, rigidity, and postural instability. This option is incorrect as the presence of alien limb phenomenon and apraxia points more towards corticobasal syndrome. Multiple system atrophy (Option C) : A Parkinsonian syndrome with features of autonomic dysfunction, such as orthostatic hypotension, and cerebellar signs. This is incorrect as there is no mention of autonomic or cerebellar dysfunction in the patient. Progressive supranuclear palsy (Option D) : A disorder that presents with early postural instability, vertical gaze palsy, and parkinsonism. This option is incorrect because the patient does not display the characteristic eye movement abnormalities seen in PSP. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page: 1115.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 8,
      "question": "A 65-year-old man presents with his family, who report that over the past year, he has developed significant personality changes. He has become socially inappropriate, often acting impulsively and showing a lack of empathy. He also struggles to initiate tasks and frequently forgets appointments. On examination, his language production is impaired, though his comprehension remains intact. What is the most likely diagnosis?",
      "options": {
        "A": "Alzheimer's disease",
        "B": "Vascular dementia",
        "C": "Frontotemporal dementia (FTD)",
        "D": "Lewy body dementia"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Frontotemporal dementia Explanation: A neurodegenerative disorder affecting the frontal and temporal lobes, leading to personality changes, disinhibition, difficulty initiating tasks, and language impairments. This is correct because the patient's symptoms, including impulsivity and language difficulties, are typical of FTD (Pick’s Disease). Frontotemporal Dementia and the Frontal Lobes: Frontal lobe functions : Executive functions: planning, behaviour control, and emotional regulation Damage to the frontal lobes leads to cognitive and behavioural changes: Disinhibition: loss of impulse control and socially inappropriate behaviour Lack of initiation: difficulty starting tasks and activities Antisocial behaviour: violation of social norms Impaired memory: mainly affects short-term memory and planning Expressive dysphasia: difficulty producing language Incontinence: loss of bladder control Core symptoms of Frontotemporal Dementia (FTD) : Progressive deterioration in personality Behavioural changes Language impairments Alzheimer's disease (Option A) : A neurodegenerative disorder that primarily causes early memory loss and spatial disorientation. This is incorrect because the patient's main symptoms are personality changes and disinhibition, not memory loss. Vascular dementia (Option B) : Usually presents with a stepwise decline in cognitive function and may include focal neurological deficits. This is incorrect as the patient's symptoms are not consistent with the stepwise deterioration typical of vascular dementia. Lewy body dementia (Option D) : Characterised by visual hallucinations, cognitive fluctuations, and parkinsonism. This is incorrect as the patient does not show the hallucinations or motor symptoms associated with this condition. Reference: Davidson’s Principles and Practice of Medicine, 24th Edition, Page 1066 www.pennmedicine.org/for-patients-and-visitors/patient-information/conditions-treated-a-to-z/picks-disease",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 9,
      "question": "A 65-year-old male presents with frequent, unexplained falls, a stiff, jerky gait, and difficulty looking down. On examination, vertical gaze palsy, axial rigidity with neck hyperextension, and square wave jerks in his eye movements are present. MRI of this patient is shown below. Which MRI finding is most characteristic of this patient's condition?",
      "options": {
        "A": "Mulberry Sign",
        "B": "Hot cross bun sign in the pons",
        "C": "Hummingbird sign",
        "D": "Target Sign"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Hummingbird sign Explanation: The patient's symptoms strongly suggest Progressive Supranuclear Palsy. In PSP, a characteristic MRI finding is selective atrophy of the midbrain with relative preservation of the pons, creating a silhouette resembling a \"hummingbird\" when viewed sagittally. This is referred to as the hummingbird sign. Progressive Supranuclear Palsy (PSP) PSP-RS is a degenerative brain disorder affecting the brainstem, basal ganglia, diencephalon, and certain parts of the cortex It typically begins with falls and subtle personality changes (mental rigidity, impulsivity, apathy) Pathology: Accumulation of abnormal tau proteins in neurons and glia, leading to neuronal inclusions that look tangle-like These changes are particularly found in areas like the subthalamic nucleus, pallidum, striatum, and brainstem structures Clinical manifestation: Oculomotor problems: Small, involuntary eye movements (square wave jerks), then slowed eye movements, particularly vertical Later stages show supranuclear ophthalmoparesis - inability to move eyes voluntarily, but reflexes remain intact Dysarthria Dysphagia Axial rigidity A stiff, unstable posture with hyperextension of the neck and a slow, jerky, toppling gait are characteristic Frequent, unexplained falls occur due to axial rigidity, inability to look down, and poor judgment Dementia - apathy, poor judgment, slow thinking, and difficulty with tasks Neuroimaging : MRI: Selective atrophy of the midbrain with preservation of pons forming the silhouette of the head of the \"hummingbird\"- \"hummingbird sign\" (Option C) Red nucleus degeneration, Quadrigeminal plate atrophy, Third ventricle enlargement, Cerebellum and pons atrophy, Frontal and temporal lobe atrophy as the disease progresses. DaTscan [Dopamine transporter single-photon emission computed tomography (SPECT)]: Reduced dopamine uptake in the striatum. Treatment: Majorly symptomatic and supportive Physical and occupational therapy can help manage movement and daily activities Poor response to levodopa Mulberry sign (Option A): It is the appearance of a well-defined lobulated lesion with a central area of heterogeneous intensities on T1WI and T2WI. It is characteristic of cavernous hemangiomas. It is not",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Neurology-Parkinsonism_And_Parkinson_S_Disease_Q9_q.png",
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 10,
      "question": "A 53-year-old male has a combination of postural instability, frequent falls, and urinary incontinence. His wife reports that he has also developed erectile dysfunction. Upon examination, he exhibits bradykinesia, rigidity, dysarthria, and postural hypotension. MRI brain image is shown below. Which of the following treatment strategies is/are most appropriate for managing his orthostatic hypotension?",
      "options": {
        "A": "Increase physical therapy",
        "B": "Initiate levodopa",
        "C": "High-salt diet and midodrine",
        "D": "Domperidone and soft diet"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) High-salt diet and midodrine Explanation: Based on the clinical manifestation and hot cross bun sign seen on the MRI, the most probable diagnosis is Shy Drager syndrome (MSA). Orthostatic hypotension management in MSA patients includes lifestyle changes like a high-salt diet and medications such as midodrine, which is an α 1-agonist that helps raise blood pressure. Shy Drager syndrome (Multiple system atrophy) Autonomic failure (orthostatic hypotension (OH) or bladder issues) + parkinsonism (MSA-p) or cerebellar problems (MSA-c) MSA-p is more common than MSA-c In a 1998 consensus statement, the term \"Shy Drager syndrome\" was formally taken out of use and placed under the categorization of \"multiple system atrophy\" (MSA) Neuropathology: Loss of neurons and presence of gliosis in the brainstem, cerebellum, and spinal cord Glial cytoplasmic inclusions stain positively (for Lewy bodies) are mainly found in oligodendrocytes MRI: In",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Neurology-Parkinsonism_And_Parkinson_S_Disease_Q10_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 11,
      "question": "A 62-year-old woman presents with noticeable changes in her movement. Her family reports that she has been experiencing increased difficulty with her balance and has developed a stooped posture. During the examination, you observe bradykinesia and rigidity, particularly in her left arm. She also mentions feeling more tired than usual and has trouble initiating movements. At this stage of her disease, which of the following areas is least likely to be affected?",
      "options": {
        "A": "Peripheral enteric system",
        "B": "Dorsal nucleus of the vagus",
        "C": "Anterior olfactory nucleus",
        "D": "Telencephalic cortex"
      },
      "correct_answer": "D",
      "explanation": "Correct Answer: D) Telencephalic cortex Explanation: In Stage 2 of Parkinson's disease, the peripheral enteric system, dorsal nucleus of the vagus, and anterior olfactory nucleus may show early signs of involvement. However, significant changes in the telencephalic cortex are typically observed in later stages (Stage 3) as cognitive impairment becomes more pronounced. Braak Staging/progression of PD Stage 1 (Pre-symptomatic) Non-motor symptoms are early Peripheral enteric system (Option A) Constipation Anterior olfactory nucleus (Option C) Anosmia Dorsal motor nucleus of the vagus (Option B) Cardiac denervation Stage 2 (Symptomatic) Substantia nigra pars compacta (Hallmark) Motor symptoms of PD Stage 3 (Symptomatic) Telencephalic cortex Cognitive impairment Reference: https://pmc.ncbi.nlm.nih.gov/articles/PMC2605160/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 12,
      "question": "A 70-year-old patient presents with resting tremor, rigidity, and bradykinesia. The physician suspects Parkinson's disease and orders a DaTscan to aid in the diagnosis. Which of the following is the primary purpose of using a DaTscan in this patient? ganglia",
      "options": {
        "A": "To detect structural abnormalities in the brain, such as hydrocephalus or masses",
        "B": "To evaluate dopamine transporter function and confirm reduced dopamine uptake in the basal",
        "C": "To measure the patient’s response to dopaminergic treatment",
        "D": "To determine the exact location of neuronal loss in the substantia nigra"
      },
      "correct_answer": "B",
      "explanation": "uptake in the basal ganglia Correct Answer: B) To evaluate dopamine transporter function and confirm reduced dopamine uptake in the basal ganglia Explanation: DaTscan evaluates dopamine transporter function and is used to confirm reduced dopamine uptake in the basal ganglia, typical in Parkinson’s disease. Investigating Parkinson’s disease (PD Clinical examination Typically sufficient to diagnose PD. MRI To rule out other conditions with similar symptoms, such as: Normal pressure hydrocephalus, Subcortical stroke. DaTscan [Dopamine transporter single-photon emission computed tomography (SPECT)] Assesses functional aspects of the dopaminergic system. Reduced dopamine uptake in the basal ganglia. It is not useful in assessing structural abnormalities. Levodopa Response A positive response to levodopa is a strong indicator of Parkinson’s Disease. Additional Imaging Used to exclude other causes like: Bleeding, Stroke, Hydrocephalus, Mass lesions, Wilson disease. To detect structural abnormalities in the brain, such as hydrocephalus or masses (Option A) : MRI or CT scans are used to detect structural abnormalities, not DaTscan, which focuses on functional dopaminergic activity. To measure the patient’s response to dopaminergic treatment (Option C) : DaTscan is not used to assess treatment response; it is a diagnostic tool for dopamine deficiency. To determine the exact location of neuronal loss in the substantia nigra (Option D) : DaTscan does not identify the precise location of neuronal loss in the substantia nigra; it assesses overall dopaminergic function in the basal ganglia. Reference: Parkinson Disease - StatPearls - NCBI Bookshelf (nih.gov)",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 13,
      "question": "A 16-year-old boy has tremors, stiffness, and difficulty walking. He has no family history of Parkinson’s disease. On examination, bradykinesia, rigidity, and postural instability were found. Genetic testing reveals a mutation associated with juvenile-onset Parkinson’s disease. Which gene is most likely responsible for his condition?",
      "options": {
        "A": "PARK-GBA",
        "B": "PARK-LRRK2",
        "C": "PARK-Parkin",
        "D": "All of the above"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) PARK-Parkin Explanation: PARK-Parkin mutations are the most common genetic cause of juvenile-onset Parkinson’s disease. Genetic Causes of Parkinson’s Disease Classical PD PARK-SNCA Missense mutations cause classical Parkinsonism. PARK-LRRK2 Clinically typical PD. Most common gene causing PD in Ashkenazi Jews and North African Berber Arabs. Most common gene responsible for sporadic cases. (Option B ruled out) PARK-VPS35 Clinically typical PD. PARK-GBA (glucocerebrosidase gene) Clinically typical PD—possibly faster progression and greater risk of cognitive impairment. Most common genetic association with PD. (Option A ruled out) Early-onset PD PARK-Parkin Often presents with dystonia, typically in a leg. Most common gene responsible for juvenile-onset PD. (Option C) PARK-PINK1 Often presents with psychiatric features. PARK-DJ1 - Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page: 3388, 3389, 3391, 3392.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 14,
      "question": "A woman is concerned about her mother, who recently developed hand tremors. She is worried because her friend's mother was diagnosed with Parkinson's disease. Which of the following is NOT a typical clinical feature of atypical parkinsonism?",
      "options": {
        "A": "Slow ocular saccades",
        "B": "Resting tremor",
        "C": "Early gait impairment",
        "D": "Poor response to Levodopa"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Resting tremor Explanation: Atypical parkinsonism usually lacks a resting tremor. Hence, the correct answer is here is resting tremor. Atypical Parkinson’s- presentation Atypical parkinsonism refers to a group of neurodegenerative conditions that are usually associated with more widespread pathology than found in Parkinson’s disease There may be degeneration of the striatum, globus pallidus, cerebellum, and brainstem, as well as the SNc) Symptoms and signs of atypical Parkinsonism: Early speech impairment Early gait impairment (Option C ruled out) Absent resting tremor (Option B) Lack of motor asymmetry Early falls Poor or no response to an adequate trial of levodopa (Option D ruled out) More aggressive clinical course Atypical Parkinsonian syndromes Multiple-system atrophy (MSA) Cerebellar type (MSA-c) Prominent cerebellar sign. Parkinson type (MSA-p) Autonomic dysfunction - orthostatic hypotension The hot cross bun sign refers to the MRI appearance of the pons when T2 hyperintensity forms a cross on axial images, representing selective degeneration of transverse pontocerebellar tracts and median pontine raphe nuclei Progressive supranuclear palsy Slow ocular saccades, eyelid apraxia, and restricted vertical eye movements with particular impairment of downward gaze (Option A ruled out) Hyperextension of the neck with early gait disturbance and falls In later stages, speech and swallowing difficulty and cognitive impairment are present The hummingbird sign (green dotted) refers to the atrophy of the midbrain tegmentum with preserved pons. The appearance resembling the head and body of a hummingbird) Corticobasal syndrome (CBS) Cortical sensory disturbances: apraxia, agnosia, focal limb myoclonus, or alien limb phenomenon (limb assumes a position in space without the patient’s awareness of its location or recognizing that the limb belongs to them) Frontotemporal dementia Behavioral, communication, and language issues",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 15,
      "question": "A 28-year-old man presents to the ophthalmologist due to difficulty with his vision following a recent corneal injury. He reports a 6-month history of tremors in his hands and increasing difficulty with speech. His family mentions changes in his behaviour, including increased irritability and episodes of abdominal pain. His eye appears as shown below. Which of the following conditions is most likely associated with this patient?",
      "options": {
        "A": "Wilson’s Disease",
        "B": "Parkinson's Disease",
        "C": "Huntington’s Disease",
        "D": "Spinocerebellar Ataxia"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Wilson’s Disease Explanation: The combination of neurological symptoms (tremors, speech difficulties, behavioural changes) and the presence of a characteristic eye finding (the ring observed) strongly suggests Wilson's disease , which involves copper accumulation leading to both hepatic and neurological manifestations. Fig: Arrow showing Kayser–Fleischer rings present on examination Neurodegenerative disorders associated with Parkinsonism Disorder Key Features Wilson’s Disease Autosomal recessive; ATP7B gene mutation Toxic copper accumulation Neurological: dysarthria, tremor, dystonia, parkinsonism Other: hepatic and psychiatric involvement Kayser–Fleischer rings present on examination (Option A) Huntington’s Disease Autosomal dominant; trinucleotide repeat disorder- CAG repeats Primarily chorea, but can have parkinsonism Juvenile form (Westphal variant) presents with parkinsonism before age 20 Spinocerebellar Ataxia (SCA) Multiple subtypes (SCA2, SCA3, SCA17) Parkinsonism can mimic idiopathic PD, especially in SCA2 Features include ataxia, peripheral neuropathy, and additional neurological signs Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) Caused by FMR1 gene premutation Symptoms: cerebellar ataxia, intention tremor, parkinsonism (bradykinesia, postural instability) Often misdiagnosed as MSA Frontotemporal Dementia with Parkinsonism(Pick’s Disease) Typically seen in behavioural variant Rigidity and",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Neurology-Parkinsonism_And_Parkinson_S_Disease_Q15_q.jpg",
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 16,
      "question": "A 55-year-old woman with a history of psychiatric disorders is being treated for her symptoms with various medications. Considering the pharmacological classes of her current treatment, which of the following medications is least likely to contribute to the development of Parkinsonism?",
      "options": {
        "A": "Haloperidol",
        "B": "Risperidone",
        "C": "Domperidone",
        "D": "Metoclopramide"
      },
      "correct_answer": "C",
      "explanation": "Correct Answer: C) Domperidone Explanation: Domperidone is a dopamine receptor blocker but does not cross the blood-brain barrier, making it less likely to cause drug-induced Parkinsonism compared to other dopamine-blocking agents. Drugs frequently cause Parkinsonism. Drug Class Examples Typical antipsychotics Chlorpromazine, Prochlorperazine, Perphenazine, Fluphenazine, Promethazine, Haloperidol, Pimozide, Sulpiride Atypical antipsychotics Risperidone, Olanzapine, Ziprasidone, Aripiprazole Dopamine depleters Reserpine, Tetrabenazine Calcium-channel blockers Flunarizine, Cinnarizine Antiemetics Metoclopramide, Levosulpiride, Clebopride Drugs infrequently cause Parkinsonism Drug class Examples Atypical antipsychotics Clozapine, Quetiapine Mood stabilizer Lithium Antiemetics Domperidone, Itopride Antidepressants SSRI: Citalopram, Fluoxetine, Paroxetine, Sertraline Antiepileptic drugs Valproic Acid, Phenytoin Management of drug-induced Parkinsonism: First-Line Management : Stop, reduce, or switch the offending drug, if possible, under medical supervision. Anticholinergic Drugs : Options like benzatropine, trihexyphenidyl, and procyclidine can help manage symptoms. Caution : Best avoided in older adults due to risks of confusion and worsening tardive dyskinesia. Alternative (Younger Patients) : Amantadine Reference: https://www.researchgate.net/publication/224811996_Drug-Induced_Parkinsonism www.sciencedirect.c om/topics/pharmacology-toxicology-and-pharmaceutical-science/domperidone#:~:text=Domperidone%20is%20a% 20selective%20antagonist,to%20cause%20extrapyramidal%20side%20effects. www.parkinsons.org.uk/sites/default/files/2018-09/FS38%20Drug%20induced%20parkinsonism_0.pdf www.sciencedirect.com/topics/neuroscience/procyclidine",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 17,
      "question": "A 68-year-old man presents with difficulty initiating movements. He experiences a resting tremor in his hands and has noticed a decline in his balance, leading to several near falls. His family mentions he seems less engaged in activities he once enjoyed. He is at risk of developing all non-motor symptoms except:",
      "options": {
        "A": "REM disorders",
        "B": "Decreased sweating",
        "C": "Restless leg syndrome",
        "D": "Urinary urgency"
      },
      "correct_answer": "B",
      "explanation": "Correct Answer: B) Decreased sweating Explanation: The patient is presenting with symptoms consistent with Parkinson's disease (PD) In Parkinson's disease, patients are more likely to experience increased sweating, along with a range of other non-motor symptoms such as REM disorders, restless leg syndrome, and urinary urgency. Category Non-Motor Symptoms Autonomic Dysfunction Neurogenic orthostatic hypotension Increased sweating Oily skin Constipation Sexual dysfunction Urinary urgency Dysphagia Neuropsychiatric Symptoms Dementia (advanced disease) Executive/visuospatial dysfunction Visual hallucinations Delusions Sleep disorders Insomnia Restless leg syndrome REM disorders Daytime sleepiness with sleep attacks Vivid dreams Sleep fragmentation (night awakenings) Depression Anxiety Apathy Anosmia Reference: Harrison’s Principles of Internal Medicine, 21st Edition, Page: 3387.",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 18,
      "question": "Which of the following statements is incorrect based on the diagnostic criteria for Parkinson's Disease (PD)?",
      "options": {
        "A": "Clinically established PD requires the absence of absolute exclusion criteria",
        "B": "Clinically probable PD can be diagnosed with two red flags and no supportive criteria",
        "C": "One red flag requires at least one supportive criterion for diagnosis",
        "D": "No more than two red flags are allowed for the diagnosis of PD"
      },
      "correct_answer": "B",
      "explanation": "criteria Correct Answer: B) Clinically probable PD can be diagnosed with two red flags and no supportive criteria. Explanation: For Clinically Probable PD, the presence of red flags must be counterbalanced by supportive criteria. Thus, having two red flags without any supportive criteria is incorrect. Parkinson’s Motor sign- Motor Sign Details Onset Unilateral at onset, with possible progression to the contralateral side Asymmetry Asymmetric symptoms, often worse on one side Tremor Unilateral resting tremor (4–6 Hz) that improves with movement and worsens with distraction Characterized by a \"pill-rolling\" quality from thumb and finger movements Rigidity Increased resistance to passive movement It can be uniform (lead pipe) or cogwheel (oscillating joint movements) Akinesia/Bradykinesia Lack of or slowness of movements; manifests as: Narrow-based shuffling gait with shortened strides Lack of arm swing Small handwriting (micrographia) Hypomimia (masked face/limited facial expressions) Hypophonia (soft speech) Postural Instability Characterized by a flexed axial posture Loss of balance during stopping/turning, and an increased risk of frequent falls Criteria for typical Parkinsonism UK Brain Bank Criteria Response to levodopa Asymmetrical tremors MDS Criteria Supportive criteria Red flags Absolute exclusion criteria Diagnosis Criteria for Parkinson's Disease: Diagnosis of Clinically Established PD requires: Absence of absolute exclusion criteria 2. At least two supportive criteria, and 3. No red flags (Option A) Diagnosis of Clinically Probable PD requires: Absence of absolute exclusion criteria The presence of red flags counterbalanced by supportive criteria If 1 red flag is present, there must also be at least 1 supportive criterion (Option C) If 2 red flags are present, there must also be 2 supportive criterion No more than 2 red flags are allowed for the diagnosis of PD (Option D) Category Criteria Absolute Exclusion Criteria Cerebellar signs Supranuclear gaze palsy Established diagnosis of BVFTD Parkinsonism restricted to lower limbs only for >3 years Treatment with antidopaminergic or dopamine-depletion agents Absence of response to levodopa Sensory-cortical loss No evidence of dopaminergic deficiency in functional imaging Other parkinsonism-inducing condition Red Flags Rapid deterioration of gait Absence of motor symptom progression over 5 years Early bulbar dysfunction Respiratory dysfunction Early severe autonomic failure Early recurrent falls due to misbalance Disproportionate anterocollis Absence of common non-motor features of disease during >5 years Pyramidal tract signs Bilateral symmetric presentation Supportive Criteria Clear and dramatic positive response to dopaminergic therapy Levodopa-induced dyskinesia Documentation of resting tremor of a limb Positive diagnostic test of either olfactory loss or cardiac sympathetic denervation on scintigraphy Reference: Harrison’s Principle of Internal Medicine, 21st Edition, Page 3387 https://www.ncbi.nlm.nih.gov/books/NBK536715/table/Ch6-t0001/",
      "image": null,
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    },
    {
      "q_no": 19,
      "question": "A 65-year-old man presents with a 2-year history of progressive motor symptoms, including a resting tremor in his right hand, increased stiffness in his limbs, a shuffling gait, reduced facial expression, and difficulty initiating movement. Using the brain diagram provided, identify the region affected by his condition.",
      "options": {
        "A": "Substantia nigra",
        "B": "Hippocampus",
        "C": "Cerebral cortex",
        "D": "Cerebellum"
      },
      "correct_answer": "A",
      "explanation": "Correct Answer: A) Substantia nigra Explanation: The symptoms are characteristic of Parkinson's Disease (PD ), also known as Paralysis Agitans, which is primarily associated with the loss of dopaminergic neurons in the substantia nigra as given in the brain diagram. This neuronal loss leads to decreased dopamine production, resulting in the motor symptoms observed, such as resting tremor, rigidity, and bradykinesia. Initial Damage Damage to substantia nigra Consequence Loss of dopaminergic neurons in substantia nigra (pars compacta) Effect Decrease in dopamine production Autopsy findings Depigmentation of substantia nigra Microscopic findings Inclusion bodies called Lewy bodies Composition of Lewy Bodies Composed of α -synuclein (intracellular eosinophilic inclusions) Accumulation of neurofibrillary tangles (Option B) is linked to Alzheimer's disease and primarily leads to cognitive decline rather than the motor issues seen in this patient. Expansion of CAG repeats (Option C): pertains to Huntington's disease, which typically presents with chorea and cognitive changes Accumulation of β -amyloid plaques (Option D) is also associated with Alzheimer's disease,",
      "image": "https://raw.githubusercontent.com/tk22kalal/mcqimage/main/pxmedicine/Neurology-Parkinsonism_And_Parkinson_S_Disease_Q19_q.png",
      "explanation_image": null,
      "chapter_heading": "Neurology-Parkinsonism And Parkinson S Disease"
    }
  ]
}
